UPTAKE AND DIFFUSION OF PHARMACEUTICAL INNOVATIONS IN HEALTH SYSTEMS - Innovation in the Biopharmaceutical Industry - page 105

Pilote, L et al . (2002). The effects of cost-sharing on essential drug prescriptions, utilization
of medical care and outcomes after acute myocardial infarction in elderly patients.
Canadian Medical Association Journal , 167(3), 246-252.
Puig-Junoy, J (2004). Incentives and pharmaceutical reimbursement reforms in Spain.
Health Policy , 67(2), 149-165.
Puig-Junoy, J (2005). What is required to evaluate the impact of pharmaceutical reference
pricing? Applied Health Economics and Health Policy , 4(2), 87-98.
Rafferty, T, K Wilson-Davis and H McGavock (1997). How has fundholding in Northern
Ireland affected prescribing patterns? A longitudinal study. British Medical Journal ,
315(7101), 166-170.
Rocchi, F, A Addis and N Martini (2004). Current national initiatives about drug policies and
cost control in Europe: the Italy example. Journal of Ambulatory Care Management ,
27(2), 127-131.
Rogers, EM (2005). Diffusion of Innovations. New York: Free Press.
Ross-Degnan, D et al . (1993). Examining product risk in context: market withdrawal of
zomepirac as a case study. Journal of American Medical Association , 270(16), 1937-
1942.
Ruof, J et al . (2002). Diffusion of innovations: treatment of Alzheimer's disease in Germany.
Health Policy , 60(1), 59-66.
Ryan, M and S Birch (1991). Charging for health care: evidence on the utilisation of NHS
prescribed drugs. Social Science & Medicine , 33(6), 681-687.
Schneeweiss, S et al . (2004). Net health plan savings from reference pricing for angiotensin-
converting enzyme inhibitors in elderly British Columbia residents. Medical Care ,
42(7), 653-660.
Schneeweiss, S, M Maclure and SB Soumerai (2002a). Prescription duration after drug
copay changes in older people: methodological aspects. Journal of American Geriatric
Society , 50(3), 521-525.
Schneeweiss, S, O Schoffski and GW Selke (1998). What is Germany's experience on ref-
erence based drug pricing and the etiology of adverse health outcomes or substitution?
Health Policy , 44(3), 253-260.
Schneeweiss, S et al . (2002b). Impact of reference-based pricing for angiotensin-converting
enzyme inhibitors on drug utilization. CanadianMedical Association Journal , 166(6),
737-745.
Schneeweiss, S et al . (2003). Clinical and economic consequences of reference pricing for
dihydropyridine calcium channel blockers. Clinical Pharmacology and Therapeutics ,
74(4), 388-400.
Schneeweiss, S et al . (2002c). Outcomes of reference pricing for angiotensin-converting-
enzyme inhibitors. New England Journal of Medicine , 346(11), 822-829.
Schoenman, JA, WN Evans and CL Schur (1997). Primary care case management for
Medicaid recipients: evaluation of the Maryland access to care program. Inquiry , 34(2),
155-170.
Schoffski, O and Graf von der Schulenburg JM (1997). Unintended effects of a costcontain-
ment policy: results of a natural experiment in Germany. Social Science & Medicine ,
45(10), 1537-1539.